Relief reports that its u.s. collaboration partner has announced that the fda has declined emergency use authorization for aviptadil for a subgroup of patients with critical covid-19 at immediate risk

Geneva, switzerland / accesswire / july 4, 2022 / relief therapeutics holding sa (six:rlf, otcqb:rlftf, rlfty) (" relief "), a biopharmaceutical company seeking to provide patients therapeutic relief from serious diseases with high unmet need, reported today that the parent company, nrx pharmaceuticals, inc. (nasdaq: nrxp) (" nrx "), of its collaboration partner with respect to aviptadil, neurorx, inc. (" neurorx "), has announced that the u.s. food and drug administration (" fda ") has declined to issue an emergency use authorization (eua) for aviptadil for a subgroup of patients that, in addition to aviptadil, also received remdesivir and continued to progress. the related nrx press release can be accessed through the following link.
NRXP Ratings Summary
NRXP Quant Ranking